Clinical Therapeutics

Editorial comment
pp. 561-561(1)
Author: Krosnick A.

Etiologies and sequelae of excessive daytime sleepiness
pp. 562-576(15)
Authors: Roth T.; Roehrs T.A.

Editorial comment
pp. 577-577(1)
Author: Krosnick A.

Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis
pp. 578-590(13)
Author: Perez E.A.

Editorial comment
pp. 591-591(1)
Author: Krosnick A.

Changing antipsychotic medication: guidelines on the transition to treatment with Risperidone
pp. 592-607(16)
Authors: Borison R.L.; Consensus Study Group on Risperidone Dosing

Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension
pp. 608-625(18)
Authors: Oparil S.; Barr E.; Elkins M.; Liss C.; Vrecenak A.; Edelman J.

Efficacy and safety of cefdinir in the treatment of patients with acute bronchitis
pp. 626-634(9)
Authors: Sperling M.J.; Puopolo A.; Griffin T.J.; Keyserling C.H.; Tack K.J.; Behalf of the Cefdinir Bronchitis Study Group

Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study
pp. 635-646(12)
Authors: Wolfe J.D.; Selner J.C.; Mendelson L.M.; Hampel F.; Schaberg A.

Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer
pp. 647-657(11)
Authors: Sharifi R.; Bruskewitz R.C.; Gittleman M.C.; Graham S.D.; Hudson P.B.; Stein B.

The CARE study: a postmarketing evaluation of ramipril in 11,100 patients
pp. 658-670(13)
Authors: Kaplan N.M.; Clinical AltaceR Real-World Efficacy CARE Investigators

Effective administration methods and dosages of interferon therapy for chronic hepatitis C
pp. 671-679(9)
Authors: Nomura H.; Kimura Y.; Tada H.; Hisano C.; Morita C.; Okamoto O.; Shiraishi G.; Higashi M.; Kashiwagi S.

Effect of manidipine chloride on various aspects of endocrine function, including plasma levels of endothelin-1 and human atrial natriuretic peptide, in patients with essential hypertension
pp. 680-686(7)
Authors: Nishikawa T.; Omura M.; Iizuka T.; Chiba S.

Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX⁽R) STATdose&unknown; System
pp. 687-699(13)
Authors: Mushet G.R.; Cady R.K.; Camak Baker C.; Clements B.; Gutterman D.L.; Davis R.

Pharmaceutical economics & health policy - Editorial comment
pp. 702-702(1)
Author: Alexander Sclar D.

Profitability, third-party reimbursement, and access to community pharmacies
pp. 703-715(13)
Authors: Carroll N.V.; Miederhoff P.A.; Waters L.W.

The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost
pp. 716-725(10)
Authors: Hotchkies L.; Grima D.T.; Hedayati S.

Effect of improved disease management strategies on hospital length of stay in the treatment of congestive heart failure
pp. 726-746(21)
Authors: Simons W.R.; Haim M.; Rizzo J.; Zannad F.

A cost-minimization analysis of intracervical prostaglandin E₂ for cervical ripening in an outpatient versus inpatient setting
pp. 747-756(10)
Authors: Farmer K.C.; Schwartz W.J.; Rayburn W.F.; Turnbull G.

Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model
pp. 757-777(21)
Authors: Marchetti A.; Tak Piech C.; McGhan W.F.; Neugut A.I.; Smith B.T.

Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life
pp. 778-788(11)
Authors: Crucitt M.A.; Hyman W.; Grote T.; Tester W.; Madajewicz S.; Yee S.; Wentz A.; Griffin D.; Parasuraman T.V.; Bryson J.